Tempus AI (NASDAQ:TEM) Trading 6.1% Higher - What's Next?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s share price rose 6.1% during mid-day trading on Monday . The stock traded as high as $56.19 and last traded at $56.13. Approximately 3,767,512 shares changed hands during trading, a decline of 33% from the average daily volume of 5,645,973 shares. The stock had previously closed at $52.90.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of Tempus AI from $50.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Piper Sandler decreased their price objective on shares of Tempus AI from $70.00 to $55.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Bank of America boosted their target price on shares of Tempus AI from $54.00 to $60.00 and gave the stock a "neutral" rating in a research report on Monday, March 3rd. Loop Capital decreased their price target on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a report on Tuesday, January 14th. Finally, JPMorgan Chase & Co. cut Tempus AI from an "overweight" rating to a "neutral" rating and lifted their price target for the stock from $50.00 to $55.00 in a research report on Tuesday, February 25th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Tempus AI has an average rating of "Moderate Buy" and an average target price of $61.08.

Tempus AI Stock Up 2.8 %

The firm's fifty day simple moving average is $48.50 and its 200 day simple moving average is $50.55. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 82,056 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $58.21, for a total transaction of $4,776,479.76. Following the transaction, the chief executive officer now directly owns 5,532,987 shares of the company's stock, valued at approximately $322,075,173.27. This trade represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Wayne A.I. Frederick sold 3,000 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $45.54, for a total value of $136,620.00. Following the sale, the director now directly owns 26,514 shares of the company's stock, valued at $1,207,447.56. The trade was a 10.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,505,134 shares of company stock worth $268,609,285 over the last three months. Insiders own 27.60% of the company's stock.

Hedge Funds Weigh In On Tempus AI

Several hedge funds have recently added to or reduced their stakes in TEM. Operose Advisors LLC purchased a new stake in Tempus AI during the 4th quarter worth about $25,000. Cherry Tree Wealth Management LLC acquired a new position in shares of Tempus AI in the first quarter valued at approximately $31,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI during the fourth quarter worth approximately $34,000. Prestige Wealth Management Group LLC grew its stake in Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after acquiring an additional 965 shares during the period. Finally, Continuum Advisory LLC acquired a new position in Tempus AI in the first quarter valued at $39,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.